Who is sponsoring NCT04941768?

NCT04941768 is sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany.

What condition does NCT04941768 study?

NCT04941768 studies Carcinoma, Renal Cell.

What is the status of NCT04941768?

NCT04941768 is currently COMPLETED.

Last reviewed 2025-11-28 · How we verify

An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)

NCT04941768 COMPLETED Results posted

The main purpose of this study is to expand knowledge on the effectiveness of Avelumab intravenous infusion in combination with Axitinib as the first-line therapy in participants with advanced renal-cell carcinoma (aRCC) in addition to the safety and tolerability under routine conditions of daily clinical practice.

Details

Lead sponsor	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Status	COMPLETED
Enrolment	105
Start date	Mon Aug 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Apr 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Carcinoma, Renal Cell

Countries

Belgium, Russia, Greece, Germany